International health officials say two experimental drugs used to treat Ebola infections appear to be saving lives in the Democratic Republic of Congo. Dr. x of the U.S. National Institute of Health called the early results some very good news. He said the new drugs may be able to improve the survival of people with Ebola. The NIH helped support the research. The findings come from a study of four different drugs that started in November of last year. But an independent monitoring group recommended last week that the study be ended early. The group recommended that all new patients should receive either of the two drugs that show the best results. The drugs are anti-bodies that work by blocking the virus in the body. One drug, REGN-EB3, is made by x Pharmaceuticals. The other, MAB1-14, was developed by the U.S. National Institutes of Health. Patients receiving these two drugs had a greater chance of survival compared to those receiving the other two drugs, the group found. An experimental vaccine is also showing signs of effectiveness against the virus. The research was designed to test the effectiveness of the drugs on as many as 725 people infected with the Ebola virus in North x and x provinces. An outbreak of Ebola in those parts of the D.R.C. has killed more than 1,800 people since August, 2018. Ebola, a kind of hemorrhagic fever, has very high rate of mortality. Dr. x of the World Health Organization said, about 75% of those who become infected and receive no special care die. But the recent study found that less than one third of patients who were infected died when they took the two new drugs. Those patients who had low levels of the virus in their blood had even better results. Among people who sought treatment early, the mortality rate was 6% for REGN-EB3, and the rate for MAB1-14 was 11%. Dr. x of the WHO said he hoped the results would persuade more patients to seek care as soon as symptoms appear. Getting people into care more quickly is absolutely vital, he said. However, treating the disease is made more difficult, because the affected areas of the eastern D.R.C. face ethnic conflict. x, Director-General of the National Institute of Biomedical Research in D.R.C., helped lead the study. He said: From now on, we will no longer say that Ebola is incurable.